Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study

Table 1 Baseline characteristics of included patients [n = 33, n (%)]

Age (yr)	63 (41–80)
Sex
Male	28 (84)
Female	5 (16)
WHO performance status
0	20 (60)
1	13 (40)
Denutrition
> 10% weight loss	10 (30)
Localization
Gastric	15 (45)
Gastro-oesophageal junction Siewert I	12 (35)
Gastro-oesophageal junction Siewert II	3 (10)
Gastro-oesophageal junction Siewert III	3 (10)
Surgery
Lewis Santy	11 (33)
Total Gastrectomy	11 (33)
Subtotal Gastrectomy	11 (33)
Clinical tumour stage
cT3/T4	7 (81)
cT1/T2	5 (18)
cTx	21 (1)
cN+	22 (77)
cN–	8 (23)
Histological type
Intestinal	28 (84)
Singet Ring cells	5 (16)
HER2 overexpressing	5 (16)

Table 2 Neoadjuvant chemotherapy adverse events

Maximal toxicity	All	Grade 3/4
All	31 (92)	10 (30)
Neutropenia	3 (10)	1(3)
Febrile neutropenia	1 (3)	1 (3)
Anaemia	2 (6)	0%
Thrombocytopenia	2 (6)	0%
Neurotoxicity	21 (63)	7 (21)
Nausea	7 (21)	0%
Asthenia	12 (36)	6 (19)
Vomiting	2 (6)	0%
Mucositis	4 (12)	2 (6)
Diarrhoea	12 (36)	3 (10)
Allergic reaction	1(3)	1 (3)

Table 3 Serious adverse events during perioperative time (n = 33)

Patients with at least one grade 3-4 adverse event during perioperative time	6 (18)
Medical complication	7 (21)
Anastomotic leak	2 (6)
Wound healing disorder	1 (3)
Pneumonia	7 (21)
Pleural complication	1 (3)
Sepsis and infection	5 (15)
Intestinal occlusion	2 (6)
Bleeding	1

Table 4 Surgical and pathological results (n = 33)

Type of surgery
Subtotal gastrectomy	11 (33)
Total gastrectomy	11 (33)
Oesophagectomy	11 (33)
Resection Grade
R0	30 (90)
R1	3 (10)
Complete (TRG 1a)†	12 (36)
Subtotal (TRG 1b)	8 (24)
Partial (TRG 2)	4 (13)
Minimal or none (TRG 3)	9 (27)
yN0	21 (63)
yN 1	6 (19)
yN2	6 (19)